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Abstract
Background: Double negative CD3
+4
28
2 TCRab splenic cells (DNCD3) can suppress the immune responses to allo and
xenografts, infectious agents, tumors, and some autoimmune disorders. However, little is known about their role in
autoimmune diabetes, a disease characterized by the reduction of insulin production subsequent to destruction of
pancreatic b-cells by a polyclonal population of self-reactive T-cells. Herein, we analyzed the function and phenotype of
DNCD3 splenic cells in young NOD mice predisposed to several autoimmune disorders among which, the human-like
autoimmune diabetes.
Methodology/Principal Findings: DNCD3 splenic cells from young NOD mice (1) provided long-lasting protection against
diabetes transfer in NOD/Scid immunodeficient mice, (2) proliferated and differentiated in the spleen and pancreas of NOD/
Scid mice and pre-diabetic NOD mice into IL-10-secreting TR-1 like cells in a Th2-like environment, and (3) their anti-
diabetogenic phenotype is CD3
+(CD4
2CD8
2)CD28
+CD69
+CD25
low Foxp3
2 iCTLA-4
2TCRab
+ with a predominant Vb13 gene
usage.
Conclusions/Significance: These findings delineate a new T regulatory component in autoimmune diabetes apart from that
of NKT and CD4
+CD25
high Foxp3
+T-regulatory cells. DNCD3 splenic cells could be potentially manipulated towards the
development of autologous cell therapies in autoimmune diabetes.
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Introduction
A unique population of T regulatory cells other than Foxp3
+
CD4
+ and IL-10-secreting TR-1 cells was recently described as
‘‘natural suppressors’’ CD3
+4
28
2/TCRab double negative T-
cells (DNCD3 cells). These cells were first described in the spleen
of adult mice [1], and human peripheral blood [2]. DNCD3 cells
represent about 1–3% of the peripheral lymphocytes in mice and
humans. Phenotypic analysis showed that an important fraction of
DNCD3 cells lack expression of NK1.1 and B220 antigens, and
express a CD44
hi memory-like phenotype [3,4]. Analysis of TCR
a and b families of DNCD3 splenocytes in healthy mice and
human subjects revealed a broad TCR Vb repertoire [2,5]. Yet,
the TCRab repertoire of DNCD3 splenic cells in autoimmune
diseases has not been investigated.
Mouse DNCD3 splenic cells can protect against lethal GVDH
in a non-MHC restricted manner [6,7]. However, the function of
DNCD3 splenic cells in healthy human subjects, where they co-
exist as a mixture of naı ¨ve MHC-restricted and antigen-
experienced cells, is still unknown [2]. A regulatory mechanism
of DNCD3 splenic cells in mice was described to rely on Fas-FasL
mediated cytolysis of CD4 and CD8 T-cells, since the defective
Fas-FasL signaling in lpr/lpr mice displaying massive lymphopro-
liferation was associated with a lack of DNCD3 cytolytic activity
[8].
It has been postulated that the DNCD3 splenic cells originate in
thymus by escaping negative selection followed by migration in
periphery where they expand upon experiencing antigen [9].
Using TREC (signal-joint TRECs and DJbTRECs) markers of
thymic differentiation, it has been shown that DNCD3 cells may in
fact undergo thymic positive selection prior to migration in the
periphery [10,11]. Thymic positive selection of IL-10-secreting,
regulatory DNCD3 cells may also occur by re-differentiation of
CD3
+4
+8
+ double positive thymocytes that interact with high-
affinity ligands expressed by thymic epithelial cells [12]. Other
studies claimed an extra-thymic pathway for DNCD3 cell
development in liver [13–15], bone marrow [16,17], or in
periphery by a mechanism of MHC class II-acquirement called
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be non-functional in vitro, antigen stimulation in vivo in the presence
of bystander IL-2 secretion by activated CD4
+ T-cells leads to
their rapid expansion in periphery [19] and IL-10 secretion [12].
Peripheral DNCD3 cells can restrict the function of T-cells
specific for allo- and xeno-antigens [20–23]. These cells can also
restrict the immune response to infectious agents [13,24] and
suppress the growth of tumor cells [25]. In contrast, the blood
circulating DNCD3 cells from SLE patients may exert inflamma-
tory effects [26]. At present, there is little information about the
role of DNCD3 peripheral cells in autoimmunity, particularly in
type-1 diabetes (T1D), a disease characterized by the reduction of
insulin production subsequent to destruction of pancreatic b-cells
by a polyclonal population of self-reactive T-cells [27,28]. The
most appropriate model for human T1D is the NOD mouse that
develops the disease spontaneously and displays a similar
pathology to humans [29]. Like in humans, the autoimmune
diabetes in NOD mice is mediated by a polyclonal population of
T-cells reactive to a variety of self-peptides [30]. Besides the MHC
and non-MHC genetic factors [31], the autoimmune diabetes in
humans and NOD mice is associated with a large number of
qualitative and quantitative defects in the T-cell compartment
[32,33].
Herein, we have analyzed for the first time the phenotype and
function of DNCD3 splenic cells from young NOD mice. These
cells displayed a TCR Vb13-biased usage apart from that of
canonical NKT cells, and lacked expression of the Foxp3 marker
of naturally-occurring CD4
+CD25
high T-reg cells. DNCD3 splenic
cells were able to proliferate in the spleen and pancreas of NOD/
Scid immunodeficient mice and pre-diabetic NOD mice, and to
differentiate into CD4
+8
+ double positive T-cells and IL-10-
secreting CD4
+TR-1 like cells upon stimulation in Th2-like
environment. Most importantly, the NOD DNCD3 splenic cells
from young NOD mice induced long-lasting protection against
diabetes transfer into NOD/Scid mice.
Methods
Ethics statement
Mice were purchased from Jackson Laboratories (Bar Harbor,
ME) and housed in pathogen-free conditions at USUHS/LAM
facility. Experiments and care/welfare were in agreement with
federal regulations and an approved protocol by the USUHS/
IACUC committee.
Mice
NOD/Lt, NON.NOD H-2
g7, and NOD.CB17-PrkdcSCID/J
immune deficient mice (NOD/Scid mice) were purchased from
Jackson Laboratories (Bar Harbor, ME). The NON.NOD mice
are congenic for the NOD H-2
g7 haplotype, and they were used as
diabetes-resistant, control mice.
Cell isolation
Thymic cells, splenic cells, and pancreatic-infiltrating lympho-
cytes were obtained from a pool of mice, or in some experiments
from individual mice. Pancreatic infiltrating lymphocytes were
isolated using either the collagenase or tissue douncing method.
For the collagenase method, 10
7 cells were treated with 4 mg/ml
proteinase-free collagenase (Sigma-Aldrich, # C6079) for 20 min
at 37uC in saline solution pH 7.5 under gentle agitation followed
by neutralization of collagenase with an equal volume of complete
RPMI media. Cells were centrifuged at 8006g, re-suspended in
saline solution containing 1% BSA, and passed through a 100 mm
filter mesh before analysis. For the tissue douncing method, the
pancreas was gently dounced, passed through a 100 mm filter
mesh (BD PharMingen, San Diego, CA), and centrifuged at 2006g
in RPMI medium supplemented with 10% heat-inactivated fetal
calf serum to remove islets and cell debris followed by
centrifugation at 8006g. Negatively-sorted CD4 T-cells were
obtained at higher than 90% purity according to FACS analysis by
cell passage through mouse CD4 subset column kit # MCD4C
according to the manufacturer’s instructions (R&D Systems,
Minneapolis, MN). DNCD3 T-cells were isolated either by
depletion of CD4 and CD8 T-cells using tandem CD4 and CD8
mouse column kits (# MCD4C and #MCD8C 1000, R&D
Systems), or by FACSAria cell sorter (BD, San Jose, CA) at 98%
purity (Figure S1). For purification of DN, DP, and SP4 T-cell
subsets, single cell suspensions were triple stained with CD3 Ab-
FITC, CD4 Ab-PE, and CD8 Ab-PerCP conjugates (BD
PharMingen, CA) and then FACS-sorted in 3 simultaneous
windows in a FACSAria instrument. In some experiments, the
TCRcd/NK cell depletion of FACS-sorted DNCD3 splenocytes
was carried out by incubation of cells with 2 mg/10
6 cells of anti-
mouse TCRcd Ab-PE (clone #GL3, BD PharMingen, San Jose,
CA) and 2 mg/10
6 cells of anti-asialo-GM1 Ab-PE conjugates
(clone #SH34, ATCC) followed by incubation with anti-PE Abs
coupled to magnetic beads and passage on MACS paramagnetic
columns according to the manufacturer’s instructions (Miltenyi
Biotech Inc., Auburn, CA).
Cell cycle divisions
FACS-sorted DNCD3 splenic cells (10
6 cells) were incubated on
ice for 30 min in RPMI 1640 medium with 2.5 mg carboxyfluor-
escein succinimidyl ester (CFSE, Sigma-Aldrich, St. Louis, MO).
The reaction was stopped by washing the cells for 10 min at
8006g and 4uC with RPMI medium supplemented with 10%
FCS, followed by one wash in phosphate buffer saline (PBS) prior
to infusion in NOD/Scid mice. CSFE labeling of cells in vivo was
carried out according to our protocol [34]. Briefly, young NOD
littermates of various ages were injected intraperitoneally (i.p.) with
0.1 mg CFSE (Sigma Chemicals, Inc, New Jersey, NJ) per gram of
body weight. Seven days post-CFSE injection the total spleen cells
were harvested and stained with various Ab-dye conjugates (BD
PharMingen, San Jose, CA). Cell cycle divisions of the CFSE-
labeled cells were detected in FACS-gated cell populations based
on CFSE dilution factor using a LSR II instrument and WINlist
analysis software 3D 5.0. (BD Biosciences).
Single-Cell Flow Cytometry
Single-cell suspensions of thymocytes, splenocytes, or pancreatic
infiltrating lymphocytes were phenotyped by 4-color staining in
FACS using various Ab-dye conjugates specific for T-cell surface
antigens (BD PharMingen). Differences in the mean fluorescence
intensity (MFI) due to the cell size and signal-to-noise autofluo-
rescence were compensated using the WINlist analysis software
(Verity Software, Topsham, ME) during the data acquisition in a
LSR II Becton Dickinson instrument.
Cell cultures and cytokines assays
Single-cell suspensions (10
6 cells) from spleens pooled from each
group of mice were cultured in 96-well plates for 1, 3, or 5 days in
RPMI medium supplemented with 10% FCS in the presence or
absence of 2.5 mg/ml of each CD3e Ab (ATCC, #2C11) and
CD28 Ab (ATCC, #7D4). In some experiments, negatively-sorted
DNCD3 splenic cells on mouse CD4/CD8 tandem columns cells
were cultured for 5 days in Th1 conditioned medium (10% FCS
RPMI medium supplemented with 10 U/ml rIL-12, 10 mg/ml
anti-IL-4 mAb, and 2.5 mg/ml CD3/CD28 Abs) or in Th2
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CD3/CD28 Abs). The cytokine secretion in cell culture superna-
tants was measured by ELISA kits using the manufacturer’s
protocol (BioSource International, Camarillo, CA). For detection
of Foxp3 gene expression, the FACS-sorted DNCD3 splenic cells
were stimulated for 1 day with CD3 and CD28 mAbs in T-reg
conditioned medium containing TGF-b 100 ng/10
6 cells).
RT-PCR
RNA was isolated using the PureLink RNA purification system
(Invitrogen, Carlsbad, CA) from various cell subsets, i.e., negatively-
sorted CD4 splenic T-cells, or FACS-sorted DNCD3 splenic cells or
DN, DP, and CD4 single positive thymocytes (SP4) stimulated or
not under Th1, Th2, or T-reg conditions. Total RNA (4 ng) was
used to prepare first-strand cDNA (One Step RT-PCR kit, Qiagen,
Valencia, CA) following the manufacturer’s protocol. The specific
primer pairs for Foxp3 were: (forward) 59 CAGCTGCCTA-
CAGTGCCCCTAG, and (reverse) 59 CATTTGCCAGCAG-
TGGGTAG; pre-TCRa (forward) 59CTGCAACTGGGTCAT-
GCTTC39 and (reverse) 59TCAGAGGGGTGGGTAAGATC39),
and for RAG2 (forward) 59TGCTAACTTGTATAGAATAA-
GAGT and (reverse) 59TCTTCTGTTGATGTCTGACTGT T).
Thespecific primers forGATA3, NF-ATc, STAT4, STAT6, T-bet,
IL-10, b-actin, and GAPDH were purchased from Applied
Biosystems. PCR products (25 mL) were electrophoresed in
ethidium bromide/1.5% agarose gels and the amplicon bands were
visualized in a KODAK imaging system.
Adoptive cell transfer protocols
Groups of 1–2 month-old NOD/Scid female mice were infused
i.p. with either diabetogenic spleen cells from hyperglycemic NOD
mice (control diabetes), or FACS-sorted DNCD3 splenic cells, or
co-infused with FACS-sorted DNCD3 splenic cells and diabeto-
genic cells, or TCRcd /NK-depleted, FACS-sorted DNCD3
splenic cells from young NOD or NON.NOD (control) mice. In
some experiments, infusion of DNCD3 splenic cells was followed
either by i.v. injection of 4 doses of 100 mg/mouse of neutralizing
IL-10 Ab (clone #JES-2AS, ATCC) prior to the co-infusion of
diabetogenic cells, or by i.p. injection of CFSE as described. The
DNCD3 cell preparations were co-infused either at the same time
with diabetogenic splenocytes or 1 month prior to infusion of
diabetogenic splenocytes. Adoptively cell transferred NOD/Scid
mice were tested for blood glucose levels on a weekly-basis via
optical bleeding using the Ascensia CONTOUR glucose strips
(Bayer, City, IN). Mice were considered diabetic after two
consecutive glucose readings greater than 200 mg/dL. Glucose
tolerance tests in some groups of adoptively cell transferred NOD/
Scid mice were carried out by i.p. injection of 60 mg glucose in
saline per mouse followed by glycemia readings at various time
intervals.
Immunohistochemistry
Paraffin-embedded sections of pancreata were stained with
hematoxylin-eosin to identify infiltrating lymphocytes. The extent
of insulin secretion by pancreatic b-cells was estimated in adjacent
pancreatic sections by staining with a rabbit anti-insulin Ab (1:200
dilution) revealed by a goat anti-rabbit IgG-horseradish peroxidase
(HRP)-conjugate (Santa Cruz Biotech, Santa Cruz, CA).
Statistic analysis
Significance of survival and diabetes incidence in NOD/Scid
mice receiving various cell preparations was compared with that of
control groups (diabetogenic T-cells alone) by the Kaplan-Meier
test, and the significance of intra-group individual variations was
determined by Kruskal-Wallis non parametric variance test. The
significance (p#0.005) of individual differences in frequency of
DNCD3 thymocytes and splenocytes from female and male NOD
littermates of different ages was estimated by the paired-Student’s
t-test.
Results
Young NOD mice display high frequency of DNCD3
splenic cells
Previous studies showed no significant differences in the size of
peripheral T-cell compartment between NOD and other mouse
strains like BALB/c, B6, and CBA mice [35]. We measured the
DNCD3 cell population size in the thymus and spleen of age-
matched NOD and NON.NOD (control) males and females
(n=18 mice per group) from 3 different litters by FACS at several
time-points after birth (Figure 1A). The number of DNCD3 cells
was lower in the thymus than spleen when analyzed between 2 to
28 days after birth in both male and female NOD mice (Figure 1B).
The highest number of DNCD3 thymocytes in newborn NOD
mice was detected 7 days after birth in males, but not female
littermates.
The spleen of both male and female NOD mice showed a
gradual increase in the number of DNCD3 cells with a peak at day
14 after birth (10–22% of the entire CD3
+ cell compartment)
(Figure 1C), which was followed by a decline up to 1–3% of the
entire CD3
+ cell population some 28 days after birth. This was
consistent with previous data showing a relative low number of
DNCD3 peripheral cells in NOD mice older than 5 weeks [36].
These data indicated that regardless the gender, the number of
DNCD3 splenic cells in NOD mice was relatively high during the
postnatal period, and sharply declined in the adulthood.
NOD DNCD3 splenocytes are not diabetogenic, but
rather tolerogenic
Several studies indicated that peripheral DNCD3 cells are
endowed with regulatory functions. Since the number of DNCD3
splenic cells was relatively high in young NOD mice, we first tested
their function in vivo. To our knowledge, a single report described a
regulatory function of DNCD3 splenic cells in a double transgenic
mouse model for T1D [37]. In this model, the mice express a TCR
specific for LCMV gp33–41 peptide and the LCMV gp protein
expressed in b-pancreatic cells. Diabetes in these mice does not
develop spontaneously, and it could be induced only by parenteral
co-administration of gp33 peptide and a CD40 agonist antibody.
Enrichment of DNCD3 splenic cell number in these mice by
adoptive transfer was associated with a delay in the onset of
diabetes. However, the transgenic mouse models for autoimmu-
nity have two major caveats. First, the autoimmunity is limited to a
single antigen in contrast to the polyclonal antigen-specificity of T-
cells in humans and NOD mice. Second, the transgenic mouse
models display aberrant expression of peptide-specific TCRa and
b transgenes, which bypasses the thymic negative selection and
consequently lead to the escape of an unusual large number of
autoreactive T-cells in periphery [38].
Herein, we compared the function of DNCD3 splenic cells from
young NOD H-2
g7and age-matched NON.NOD H-2
g7 (diabetes
resistant) mice in adoptive cell transfer experiments using NOD/
Scid recipients. Naı ¨ve (non-manipulated) NOD/Scid mice are
normoglycemic and their pancreatic b-islets have robust insulin
secretion. NOD/Scid mice infused with diabetogenic splenocytes
(5610
5 cells/mouse) isolated from 4–5 month-old hyperglycemic
NOD mice (diabetes-control group) developed hyperglycemia and
Regulation of Type 1 Diabetes
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NOD/Scid recipients infused with DNCD3 splenocytes
(5610
5 cells/mouse) isolated from 14 day-old NOD or NON.-
NOD mice developed hyperglycemia (Figure 2B) or pancreatic
insulitis (not shown), and they all showed a normal glucose
tolerance test 2 months after the cell transfer (Figure 2C). This
clearly showed a lack of diabetogenicity of DNCD3 splenic cells
from young NOD mice when parked into NOD/Scid immuno-
deficient mice.
We next tested the tolerogenicity of NOD vs. NON.NOD
DNCD3 splenocytes in the NOD/Scid system. Groups of NOD/
Scid mice received DNCD3 splenocytes (5610
5 cells/mouse) from
a pool of 14 day-old NOD or NON.NOD control females at the
same time with diabetogenic splenocytes (5610
5 cells/mouse)
from 4–5 month-old hyperglycemic NOD mice. All the NOD/
Scid recipients in these groups developed hyperglycemia, although
those co-infused with NOD DNCD3 splenocytes and diabetogenic
cells, but not those infused with NON.NOD DNCD3 splenocytes
and diabetogenic cells showed a 2 to 3-week delay in hypergly-
cemia onset (Figure 2D). At first, the NOD DNCD3 splenic cells
showed a tolerogenic effect that was insufficient to abrogate the
onset of hyperglycemia in NOD/Scid mice co-infused at the same
time-point with diabetogenic splenocytes. In contrast, five of six
NOD/Scid mice in one group, and all five mice in another group
receiving the same number of DNCD3 splenocytes (5610
5 cells/
mouse) from 14 day-old NOD females 1 month prior to co-
infusion of diabetogenic splenocytes (5610
5 cells/mouse) re-
mained normoglycemic for 13 weeks. A single mouse in these
two groups developed late hyperglycemia (10 weeks) after co-
infusion of diabetogenic cells (Figure 2E). Protected NOD/Scid
recipients showed normal morphology of the pancreatic islets and
strong b-cell secretion of insulin 13 weeks after co-infusion with
diabetogenic cells (Figure 2F, middle rows). The only mouse in
these groups that developed late hyperglycemia showed pancreatic
insulitis and reduction in b-islet insulin secretion (Figure 2F,
bottom rows). Hyperglycemia and pancreatic insulitis were
Figure 1. Frequency of NOD DNCD3 thymic and splenic cells. Total thymocytes and splenocytes from individual NOD and NON.NOD control
males and females were harvested at various time-points after birth, stained with CD3-PE, CD4-PE-Cy7, and CD8-PerCP mAb-conjugates, and the
frequency of CD3
+4
28
2 (DNCD3) cells was measured by FACS. Panel A, cells gated based on the forward and light scatter to identify viable
populations. Panel B, kinetics of thymic vs. splenic DNCD3 cell development in newborn NOD mice. Panel C, kinetics of thymic vs. splenic DNCD3 cell
development in newborn NON.NOD control mice. Shown are the individual variations (mean 6 SD) in each age group.
doi:10.1371/journal.pone.0011427.g001
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5 cells) from a pool
of 4–5 month-old diabetic (hyperglycemic) NOD mice were injected i.p. into 4 week-old NOD/Scid female mice (n=6, control diabetes group) and
glycemia was measured on a weekly-basis. Dotted horizontal line at 200 mg/dL indicates the upper limit of euglycemia as previously established in a
cohort of 12 non-treated, 4 week-old NOD/Scid females. Colored symbols refer to individual mice. Arrow on the X-axis indicates the time of cell
infusion. Panel B, FACS-sorted DNCD3 splenic cells (5610
5 cells) from a pool of 14 day-old NOD (dark symbols) and NON.NOD females (light symbols)
(n=20 donors per group) were infused i.p into 4 week-old NOD/Scid females (n=6 recipients per group) and glycemia was monitored on a weekly-
basis. Shown are the glycemia values (mean 6 SD) in each group of NOD/Scid recipients. Arrow on the X-axis indicates the time of cell infusion. Panel
C, glucose tolerance test carried out in NOD/Scid mice 2 months after infusion of DNCD3 splenocytes from 14 day-old NOD mice. Shown are two
representative NOD/Scid mice infused with diabetogenic splenic cells from a hyperglycemic NOD mouse and tested 2 weeks post-cell infusion
(diabetes control, red symbols); a representative NOD/Scid mouse infused with DNCD3 splenocytes from 14 day-old NOD mice (grey symbols), and a
representative NOD/Scid mouse infused with DNCD3 splenocytes from 14 day-old NON.NOD mice (white symbols). Arrow on the X axis indicates the
time of glucose i.p. injection (60 mg/mouse). Panel D, FACS-sorted DNCD3 splenic cells (5610
5 cells) from 14 day-old NOD or NON.NOD females (pool
of 20 mice per group) were co-infused i.p. in the same day with diabetogenic splenocytes (5610
5 cells) from diabetic NOD females into 4 week-old
NOD/Scid females (n=6 recipients per group). Shown are the glycemia values in individual NOD/Scid recipients of DNCD3 splenocytes from NOD
mice (dark symbols) or NON.NOD control mice (blue symbols). Arrows (dark and red) indicate the same time of cell co-infusion. Panel E, FACS-sorted
DNCD3 splenic cells (5610
5 cells) from 14 day-old NOD females (pool of 20 mice) were infused i.p. and 1 month later co-infused i.p. with
diabetogenic splenocytes (5610
5 cells) from diabetic NOD females into 4 week-old NOD/Scid females (n=6 recipients/group). Shown are the
glycemia values in individual NOD/Scid recipients. The time-points of cell infusion with DNCD3 splenocytes (dark arrow) and co-infusion of
diabetogenic cells (red arrow) are indicated. A single NOD/Scid recipient became hyperglycemic 10 weeks after co-transfer, whereas the other 5 NOD/
Scid mice remained euglycemic (p=0.002 for the group of protected NOD/Scid mice by NOD DNCD3 splenocytes as compared with non-protected
NOD/Scid mice by NON.NOD DNCD3 splenocytes). Panel F, hematoxylin-eosin staining of paraffin-embedded sections of the pancreas for a
representative euglycemic, non-injected NOD/Scid mouse (row 1, left panel); an euglycemic NOD/Scid mouse 13 weeks after co-transfer of NOD
DNCD3 splenocytes with diabetogenic splenocytes as in panel E (row 2, left panel); and the only hyperglycemic NOD/Scid mouse 13 weeks after cell
co-transfer of NOD DNCD3 splenocytes with diabetogenic splenocytes as in panel E (row 3, left panel). Shown is the staining of adjacent pancreatic
cross-sections from the same mice with a rabbit anti-mouse insulin Ab-HRP conjugate (rows 1–3, right panels). Panel G, FACS-sorted DNCD3 splenic
cells (5610
5 cells) from 14 day-old NON.NOD females (pool of 20 mice) were infused i.p. into 4 week-old NOD/Scid females (n=6 recipients per
group) and 1 month later co-infused i.p. with diabetogenic splenocytes (5610
5 cells) from diabetic NOD females. Shown are the glycemia values in
individual NOD/Scid recipients. The time-points of cell infusion with DNCD3 splenocytes (dark arrow) followed 1 month later by co-infusion of
diabetogenic cells (red arrow) are indicated. All NOD/Scid recipients became hyperglycemic within 3 to 4 weeks as the diabetes control group did
(see panel A) (p#0.001 for two combining experiments). Each panel represents one of two representative experiments for which the significance of
diabetes incidence was p #0.005.
doi:10.1371/journal.pone.0011427.g002
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DNCD3 splenic cells (5610
5 cells/mouse) infused 1 month prior
to co-infusion of diabetogenic splenocytes (5610
5 cells/mouse)
(Figure 2G).
There is a body of evidence demonstrating that the number and
function of NK and NKT cells in the NOD mice are deficient.
Adoptive transfer of NK cells in some mouse models of diabetes
can prevent/delay the onset of disease [39–41]. Also, the function
of CD3
+(4
28
2) double negative TCRcd
+ cells in autoimmune
diabetes remains poorly defined. Herein, we tested whether the
anti-diabetogenic function of NOD DNCD3 splenic cells could be
attributed to some extent to a small number (1–2%) of
contaminating CD3
+(4
28
2) double negative TCRcd
+ cells in the
preparations of FACS-sorted DNCD3 splenic cells. For this, we
injected a group of NOD/Scid mice with FACS-sorted DNCD3
splenocytes (5610
5 cells/mouse) isolated from 14 day-old NOD
females followed by CFSE in vivo labeling, as described. Seven days
later, the CFSE dilution factor in CD4
28
2-gated TCRcd cells
indicated a lack of cell division (Figure S2). Furthermore, a
separate group of NOD/Scid mice was infused with TCRcd/NK-
depleted, FACS-sorted DNCD3 splenocytes (5610
5 cells/mouse)
isolated from 14 day-old NOD females followed by co-infusion of
diabetogenic cells (5610
5 cells/mouse) 1 month later. All the
recipient mice in this group remained normoglycemic until the
present time (8 weeks after the cell co-transfer, data not shown).
These data clearly ruled out the possibility that a small number of
contaminating TCRcd
+ cells or NK cells in the FACS-sorted
DNCD3 cell preparations could expand and contribute to the
DNCD3 anti-diabetogenicity in the NOD/Scid system.
Together, these results demonstrated that the DNCD3 splenic
cells from young NOD mice are not diabetogenic when parked in
immunodeficient mice, but rather exerted a tolerogenic (anti-
diabetogenic) effect. A lag period was required for the NOD
DNCD3 splenic cells to develop a strong anti-diabetogenic effect
in the NOD/Scid mice. In contrast, the NON.NOD DNCD3
splenic cells exerted neither diabetogenic nor anti-diabetogenic
effects in NOD/Scid mice.
NOD DNCD3 splenocytes proliferate and differentiate in
vivo
The ability of DNCD3 splenic cells to proliferate in some mouse
strains has been previously described [21,42]. Since the NOD
DNCD3 splenic cells required a lag period (1 month) of being
parked in NOD/Scid mice in order to exert a strong anti-
diabetogenic effect, we investigated the fate of these cells in NOD/
Scid mice. For this, a group of NOD/Scid mice was infused with in
vitro CFSE-labeled DNCD3 splenic cells (5610
6 cells/mouse) that
were FACS-sorted from a pool of 14 day-old NOD female mice,
and 7 days later the CFSE
+ cells were harvested from the spleen
and pancreas of recipient mice and the cell cycle division was
measured by FACS in the CD3-gated population. Some 12% and
respectively 32% of CFSE-labeled DNCD3 cells advanced to 5–6
cycles of cell division in the spleen (Figure 3A, upper panels) and
pancreas (Figure 3A, lower panels). Some 35% and respectively
42% of the CFSE
+-proliferating cells expressed both the CD4 and
CD8 markers (CD3
+(4
+8
+) double positive T-cells), and 52% and
respectively 21% expressed only the CD4 marker (CD3
+4
+8
2
single positive T-cells) in the spleen and pancreas. A few CFSE
+
labeled CD3
+(4
28
+) single positive T-cells were detected in the
spleen (0.8%) and pancreas (3.4%) of NOD/Scid recipients. These
results indicated a process of DNCD3 cell differentiation into more
mature T-cells after being parked in the NOD/Scid immunode-
ficient mice. The analysis of DNCD3 splenic cells in CFSE-
labeled, non-manipulated NOD mice at various time-points after
birth also showed a gradual increase in their rate of proliferation
with the peak at day 14 after birth (Figure S3), which was
consistent with our previous data showing a high percent of
DNCD3 cells found in the spleen of young NOD mice 14 days
after birth.
Furthermore, the CD3
+ pancreatic infiltrating lymphocytes
from CFSE-injected, 4 month-old pre-diabetic NOD mice also
showed the presence of CD3
+(4
+8
+) double positive T-cells with a
3-times higher frequency in males than females (57% vs. 22%)
(Figure 3B). The pancreas of CFSE-injected, 4 month-old pre-
diabetic NOD females showed a significantly higher number of
CD3
+(4
28
+) single positive T-cells (5.3%) as compared with their
male littermates (0.6%). Identification of CD3
+(4
+8
+) double
positive T-cells by FACS in single-cell suspensions of pancreatic
infiltrating lymphocytes from pre-diabetic NOD mice was possible
only by douncing the pancreas instead of using the collagenase
method of tissue digestion. We found that two different
preparations of collagenase had drastically altered the phenotype
of T-cells, since shortly after digestion of thymus with collagenase
the CD4
+8
+ double positive thymocytes lost the surface expression
of CD4 and CD8 antigens to a large extent (Figure S4), most
probably due to contaminating proteases in collagenase prepara-
tions. The presence of double positive T-cells in the pancreas of
pre-diabetic mice suggested a process of cell differentiation similar
to that observed in the NOD/Scid mice infused with NOD
DNCD3 splenocytes.
A number of cellular and molecular events delineate T-cell
differentiation in the thymus. Among these events, the expression
pattern of CD44 vs. CD25 markers together with the expression
patterns of RAG2 gene and pre-TCRa chain provide a quite
accurate assessment of DN1-4 stages of differentiation in thymus.
RAG2 gene is critical for transition of DN to DP stage of thymic
differentiation, and its expression is gradually diminished in DP
thymocytes and mature SP4 T-cells. At the same time, pTCRa
gene expression is detected in the DN3-4 stage of thymic
differentiation, and its expression diminishes to undetectable levels
in DP stage and mature SP4 T-cells [43–45]. We first compared
the pattern of CD25/CD44 expression in DNCD3 thymocytes
and splenocytes to that of pancreatic infiltrating DNCD3
lymphocytes isolated by the tissue douncing method. The thymus
contained 12–13% cells with a CD44
+25
2 (DN1) phenotype, 44–
55% with a CD44
+25
+ (DN2) phenotype, 21–31% with a
CD44
225
+ (DN3) phenotype, and 11–13% with a CD44
225
2
(DN4) phenotype (Figure 4). While the DN2 cells represented the
major population in thymus (44–55%), most of DNCD3
splenocytes (90% in females and 86% in males) expressed a
CD44
+25
2 phenotype, whereas most of pancreatic DNCD3 cells
expressed a CD44
225
+ phenotype. The pattern of RAG2 gene
and pTCRa chain expression was also similar in the thymic,
splenic, and pancreatic infiltrating DNCD3, DP, and mature SP4
T-cells isolated from 4–5 month-old pre-diabetic NOD females
(Figure 4B). Similar results were obtained in pre-diabetic NOD
males (data not shown). According to these results, and considering
that CD3
+(4
+8
+) double positive T-cells were almost undetectable
in the spleen of 4–5 month-old pre-diabetic NOD mice (0.2–0.6%)
while being present in the pancreatic infiltrating lymphocytes, it is
not unlikely that the pancreatic infiltrating CD3
+(4
+8
+) double
positive T-cells derived from differentiation of pancreatic infiltrat-
ing DNCD3 cells.
The differentiation potential of DNCD3 splenic cells was also
observed upon in vitro Th2 stimulation, but not CD3/CD28 or
Th1 stimulation. Thus, a 3-day stimulation of negatively-sorted
DNCD3 splenic cells isolated from 14 day-old NOD mice in Th2
conditioned medium led to the appearance of CD3
+(4
+8
+) double
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+(4
+8
2) single positive T-cells, and few
CD3
+(4
28
+) single positive T-cells (.1%) (Figure 5A, right panel).
Aliquots of these cell cultures showed predominant IL-10 secretion
after 3 days of culturing (Figure 5B). Although the IL-10 mRNA
expression was absent in non-stimulated NOD DNCD3 splenic
cells, its expression was detected by RT-PCR after 3 days of Th2-
stimulation, which coincided with the appearance of mature CD4
T-cells in the cell cultures (Figure 5C). In contrast to Th2-
stimulated cultures, there were no double positive T-cells and
single positive T-cells, nor cytokine secretion detected in DNCD3
splenic cells stimulated for 3 and 5 days in Th1 conditions or
CD3/CD28 Abs alone (Figure 5A left panel, and 5B). After 3 days
of Th1-stimulation, the DNCD3 cell cultures showed expression of
both Th1 and Th2 transcriptional factors, whereas the Th2-
stimulated cultures lacked expression of Th1 transcription factors
T-bet and STAT4 (Figure 5D). These results clearly indicated a
biased differentiation of DNCD3 splenic cells into a TR-1 like
phenotype.
To test whether IL-10 secretion by DNCD3 differentiating
splenocytes plays a role in protection against diabetes transfer in
NOD/Scid mice, a group of NOD/Scid mice was first infused
with TCRcd/NK-depleted, FACS-sorted DNCD3 splenocytes
(5610
5 cells/mouse) from 14 day-old NOD females followed by
i.v. injection of 4 doses of IL-10 neutralizing Ab (100 mg/mouse
every other week). On day 30 after cell infusion and anti-IL-10
treatment, the NOD/Scid recipients were co-infused with
diabetogenic splenocytes (5610
5 cells/mouse) from a pool of
hyperglycemic NOD mice. Under these conditions, all five
recipient mice developed hyperglycemia within 4 weeks after co-
infusion of diabetogenic cells (data not shown), indicating that IL-
10 secreted by DNCD3 differentiating splenocytes played a critical
role to their anti-diabetogenic effect.
Together, these results indicated that the DNCD3 splenic
cells from young NOD mice can differentiate into more mature T-
cells in a lymphopenic/immunodeficient environment like the
NOD/Scid mouse, as well as in a well-established autoimmune
Figure 3. In Vivo proliferation and differentiation of NOD DNCD3 splenic cells. FACS-sorted DNCD3 splenic cells from a pool (n=20) of 14
day-old NOD females were labeled ex-vivo with CFSE and injected i.p. into three NOD/Scid mice (5610
6 cells per mouse). Seven days post-infusion,
the spleen and pancreas of recipient mice were harvested, the cells were isolated by douncing, and single-cell suspensions were pooled and stained
with CD4-PE-Cy7 and CD8-PerCP mAb-dye conjugates. Shown are the cycles of cell division of CD3
+4
28
2 (DN), CD3
+4
+8
+ (DP), CD3
+4
+8
2 (SP4), and
CD3
+4
28
+ (SP8) cell populations from the spleen (panel A, upper histograms) and pancreas (panel A, lower histograms) of the NOD/Scid infused with
CFSE-labeled DNCD3 splenocytes. The percent in each cell subset (grey histograms) and CFSE-cell intensity (dark peaks, cycle ‘‘0’’ of division) are
indicated. Panel B, pancreatic infiltrating lymphocytes from 4 month-old NOD females (left histogram) and males (right histogram) (n=8 mice/group)
were isolated and stained for CD3, CD4 and CD8 markers as described. Shown are the mean values (%) of DN, DP, SP4 and SP8-like cell populations
for two representative experiments 6 SD values for individual male and female NOD mice.
doi:10.1371/journal.pone.0011427.g003
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splenic cells were able to differentiate preferentially into IL-10-
secreting TR-1 like (anti-diabetogenic) cells upon Th2 stimulation.
NOD DNCD3 splenocytes express a unique phenotype
We next analyzed the expression level of several protein
receptors involved in T-cell effector functions in relation to the
anti-diabetogenicity of DNCD3 splenic cells from young NOD
mice. The CD28 co-stimulatory molecule plays an important role
in T-cell priming and differentiation, and its expression level is
increased early after T-cell activation [46]. The frequency of NOD
DNCD3 CD28
+ splenocytes (78–86%) was similar to that of
mature, splenic CD3
+4
+28
+ T-cells (92–98%) (Table 1). However,
the average number of DNCD3 CD28
+ splenocytes in NOD
females was constantly higher (86%) than in the male littermates
(78%). On average, the expression level of CD28 on DNCD3
splenocytes measured by the mean fluorescence intensity (MFI) in
single-cell FACS analysis was also similar to that of mature, splenic
CD3
+4
+ T-cells (MFI=1922199 vs. 180–187).
A relative high number of DNCD3 splenocytes showed
expression of the CD69 early marker of activation (16.8–19.2%)
and CD25 late marker of activation (13.4–19.2%) as compared
with mature, splenic CD3
+4
+8
2 T-cells (CD69
+, 10.3–11.4% and
CD25
low, 2.5–6.2%) (Table 1). This suggested that a significant
fraction of DNCD3 splenocytes are under a continuous state of
activation, which is in line with the hypothesis that DNCD3 cells
can be activated in peripheral lymphoid organs [21,42].
A high level of CD25 expression (CD25
high) on CD4 T-cells is
the hallmark of naturally-occurring CD4
+Foxp3
+ T-regulatory (T-
reg) cells [47]. The number of NOD DNCD3 CD25
high splenic
cells was very low (Table 1), and Foxp3 expression was
undetectable in their quiescent state or after stimulation with
CD3/CD28 Abs alone, or by culturing in a Th1, Th2, or T-reg
conditioned medium containing TGF-b (Figure S5) The CTLA-4
co-receptor is also expressed lately on the activated T-cells, and it
inhibits the TCR signaling through phosphatase-induced tyrosine
de-phosphorylation of TCR f-chains [48]. High intracellular
CTLA-4 expression (iCTLA-4) is increased in the CD4
+Foxp3
+ T-
regulatory (T-reg) cells, and it synergizes with their suppressogenic
function [49]. Co-expression of iCTLA-4 and Foxp3 in T-reg cells
has been recently reported to suppress pancreatic islet autoimmu-
nity [50.51]. In contrast to the CD28 expression on NOD
DNCD3 splenocytes, the iCTLA-4 expression was hardly detected
(0.45–0.8%). The lack of CD25
high expression and iCTLA-4/
Foxp3 co-expression on the NOD DNCD3 splenic cells in the
presence or absence of stimulation in T-reg conditioned medium
indicated that these cells are phenotypically different than the
conventional CD4
+CD25
high Foxp3
+ T-reg cells.
NKT cells represent a small fraction of the DNCD3 peripheral
pool in mice. However, the NK cell compartment is deficient in
naı ¨ve (non manipulated) NOD mice [3,4,52–54], and infusion of a
large number of competent NK cells from C57BL/6 mice in pre-
diabetic NOD mice was shown to protect against diabetes onset
[55–57]. We analyzed the expression of conventional NK
biomarkers in NOD DNCD3 splenic cells. First, the expression
of NK1.1 antigen on NOD DNCD3 splenic cells has been ruled
out, since the NOD mouse strain like the C57BL/6 and SJL
strains lacks the NK1.1 encoding allele. The number of DNCD3
splenocytes expressing the CD49b antigen recognized by DX5
mAb [58] was also insignificant (0.460.3%) as compared with
mature CD3
+4
+ T-cells from the spleen of NOD mice
(2.1761.1%) (Table 1). Also, a CD1d tetramer loaded with a-
galactosyl–ceramide surrogate of the glycosphingolipoidic moiety
that is specifically recognized by NKT cells [59], was unable to
stain the DNCD3 splenocytes from young NOD mice
(0.17%60.1% NKT cells), but it did stain mature, splenic NOD
CD3
+4
+ T-cells (2.961.1% NKT cells) (Table 1). Since these
results showed a lack of identity of NKT cells with the NOD
DNCD3 splenocytes, we next analyzed the TCR repertoire of
DNCD3 splenocytes in individual NOD mice from three different
litters at various time-points after birth. NKT cells are known to
display a biased expression of TCR Va14: Vb8.2 genes where
Va14 may also pair with Vb7o rV b2 genes as found in the Vb8
Figure 4. In Vivo detection of markers for NOD DNCD3 cell
differentiation. Panel A, Single-cell suspensions isolated by tissue
douncing of total thymocytes and splenocytes from 14 day-old
individual NOD females and males from two different litters (n=5 mice
per gender), as well as pancreatic lymphocyte infiltrates from 4–5
month-old individual pre-diabetic NOD females were stained with CD3-
Alexa 700, CD4-PE-Cy7, CD8-PerCP, CD25-APC, and CD44-FITC mAb-
conjugates, and analyzed by FACS. Shown are the mean values
(percent) of CD44 vs. CD25 expression on DNCD3 cells in each organ
and gender 6 SD. Panel B, patterns of RAG2 (upper panel) and pre-
TCRa (middle panel) mRNA expression detected by RT-PCR in the FACS-
sorted thymic, splenic and pancreatic infiltrating DNCD3, DP, and
mature SP4 T-cell subsets from a pool of 4 to 5 month-old, pre-diabetic
NOD female mice (n=6), as described. Lane 1, SP4 pancreatic infiltrating
cells; lane 2, SP4 splenocytes; lane 3, SP4 thymocytes; lane 4,D P
pancreatic infiltrating cells; lane 5, DP thymocytes; lane 6, DNCD3
pancreatic infiltrating cells; lane 7, DNCD3 splenocytes; and lane 8,D N
thymocytes. Lower panel shows the corresponding GAPDH mRNA
amplicons analyzed in the upper and middle panels. Arrows indicate
the presence of RAG2, pTCRa, and GAPDH amplicons.
doi:10.1371/journal.pone.0011427.g004
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showed a predominant Vb13 expression in both NOD males in
females. Other Vb families were well-spread, but lowly expressed,
and with no gender differences in the DN thymocytes (Figure 6A).
However, the expression of Vb4, Vb5, Vb7, Vb9, and Vb14 gene
families were undetectable 14 days after birth in both male and
female littermates. The Vb13 expression followed different kinetics
during the postnatal period, with the highest expression 7 and 21
days after birth in NOD males and females (Figure 6B). The same
distribution of Vb families was found in the spleen of 14 day-old
NOD females and males, although their expression level was
slightly higher than in the DNCD3 splenic cells (Figure 6C). This
was in agreement with the fact that Vb is rearranged only in the
DN3 stage of thymic differentiation [61]. Interestingly, only 2% of
DNCD3splenocytesexpressedtheVb8.2/3geneproducts,whereas
theVb13gene productwaspredominantly expressedatday14after
birth. The TCR Vb13 followed a different kinetics of expression
during the post-natal period in both genders (Figure 6D). These
results clearly indicated that the TCRs on NOD DNCD3
splenocytes were encoded mostly by Vb genes (95–97%) as
compared with a small number encoded by Vd genes (2–4%)
(Table 1). Together, these data argue for a unique phenotype of
NOD DNCD3 splenocytes apart from that of NKT cells. In
conclusion, the DNCD3 splenic cells of young NOD mice showed
the following predominant phenotype: CD3
+ (CD4
2CD8
2) CD28
+
CD69
+ CD25
low Foxp3
2 iCTA-4
2 TCRab
+.
Figure 5. Cytokines and transcriptional events in NOD DNCD3 splenic cells. The DN splenic cells and mature, splenic CD4
+ T-cells from a
pool (n=10) of 14 day-old female mice were negatively-selected on mouse CD4/CD8 tandem columns at 95% purity according to FACS analysis. Cells
(1610
6) were stimulated or not for 1, 3, or 5 days with a mixture of soluble CD3/CD28 Abs (2.5 mg each), or with CD3/CD28 mAbs in Th1 or Th2
conditioned medium, as described. The one-day stimulation assay was used to measure the IL-2 secretion in the culture medium. Panel A, DN splenic
cell cultures stimulated under Th1 (left panel) and Th2 (right panel) conditions, then stained 3 days later with CD4 Ab-APC and CD8 Ab-PerCP, and
analyzed by FACS. Shown is the mean values (%) of CD4
28
+ cytotoxic, CD4
+8
+ double positive, and CD4
+8
2 single positive T-cells from duplicate
cultures 6 SD. Panel B, mean values of cytokines measured in duplicate wells by ELISA in the same DNCD3 cell cultures (pg/mL 6 SD) described in
panel A. Panel C, mRNA extracted 3 days after stimulation of aliquot DNCD3 cell cultures like in panels A&B, and amplified in RT-PCR using specific
primers for IL-10. In the upper panel, lane 1, molecular markers; lane 2, non-stimulated cells after 1 day of culturing in medium alone; lane 3, CD3/
CD28 stimulated cultures; lane 4, cell cultures stimulated in Th1 conditioned medium; and lane 5, cell cultures stimulated in Th2 conditioned medium.
Lower panel shows the corresponding GAPDH mRNA amplicons for the corresponding samples analyzed in the upper panel for IL-10 mRNA
expression. Panel D, mRNA extracted 3 days after stimulation from aliquot DNCD3 cell cultures like in panels A&B, and amplified in RT-PCR using
specific primers for the major Th1 and Th2 transcription factors (lane 1, molecular markers, lane 2, STAT6; lane 3, GATA-3; lane 4, cMAF; lane 5, NF-ATc;
lane 6, STAT4, and lane 7, T-bet). Lower panel shows the corresponding GAPDH mRNA amplicons for each transcription factor. Each panel shows one
of two representative experiments.
doi:10.1371/journal.pone.0011427.g005
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T1D onset greatly depends on the balance between pancreatic
self-reactive (diabetogenic) T-cells and T-reg compartment. T-reg
cells are present in the peripheral lymphoid organs of NOD mice
some 3 days after birth, but the adult NOD mice display
quantitative and qualitative defects in the T-reg compartment [7]
including the NK cells [50,51]. Diabetes develops in NOD mice
12–14 wks after birth along with a loss in T-reg number and
function and increase in the number of diabetogenic infiltrating T-
cells in pancreas. Conceivably, the T-reg compartment may
efficiently down-regulate the diabetogenic T-cell function in
young, but not in adult NOD mice. The T-reg cell compartment
comprises a heterogeneous population of cells, among which the
recently described subset of CD3
+(4
28
2) double negative
TCRab
+ T-cells (DNCD3 cells) [62].
We found a high frequency of DNCD3 cells in the spleen of
young NOD mice, and their number sharply declined in
adulthood. DNCD3 splenic cells from young NOD mice were
able to provide long-lasting protection (13 weeks) against diabetes
transfer in NOD/Scid mice. The protection was induced only
when the DNCD3 splenocytes were parked for 1 month prior to
co-infusion of diabetogenic cells in the NOD/Scid mice. The
results of this study supported the notion that the regulatory
function of DNCD3 cells can fully develop upon differentiation in
the spleen and pancreas of NOD/Scid immunodeficient mice and
pre-diabetic NOD mice. DNCD3 peripheral cells from other
mouse strains were previously shown to proliferate in vitro and in
vivo [21,42]. Interesting enough, the rate of DNCD3 cell
proliferation in pancreas was 3 to 5 times faster in pre-diabetic
NOD males than females, which is intriguingly consistent with a 2
to 3-times lower incidence of diabetes in NOD males.
DNCD3 splenic cells from young NOD mice were able to
differentiate preferentially into IL-10-secreting CD4
+ TR-1 like
cells under Th2 stimulation. In vivo neutralization of IL-10
abrogated the transfer of disease in NOD/Scid mice, which
clearly indicated that the anti-diabetogenic effect of differentiated
DNCD3 splenic cells relied on IL-10 secretion. The ability of
peripheral DNCD3 cells from other mouse strains to secrete IL-10
was previously reported [63], and we have previously demon-
strated that the IL-10-secreting TR1-like cells prevent the T1D
onset in a double transgenic mouse model [64]. There was no
evidence of NOD DNCD3 splenic cell differentiation into
conventional CD4
+25
high T-reg cells, as the expression of
CD25
high, iCTLA-4, and Foxp3 biomarkers was absent in their
quiescent state or after in vitro stimulation under various conditions.
The DNCD3 cells were detected in the pancreatic infiltrating
lymphocytes from pre-diabetic, adult NOD mice with a similar
pattern of CD44/CD25, RAG2, and pTCRa expression to that of
DNCD3 thymocytes. The pancreatic infiltrating lymphocytes also
showed the presence of a significant number of CD3
+(4
+8
+) double
positive T-cells. A higher number of CD3
+(4
+8
+) double positive
T-cells in the pancreas than in the spleen of pre-diabetic mice may
account for the presence of higher amounts of auto-antigens in the
pancreas. Although the antigen does not seem to play a role in
DNCD3 thymic cell differentiation, previous reports indicate that
proliferation of DNCD3 splenocytes in peripheral lymphoid
organs requires the presence of antigen and IL-2 [12,19].
Together, these data argue for plasticity in the genetic program
of peripheral DNCD3 cells from young NOD mice that allows
them to differentiate in an extra-thymic environment into mature
T-cells with regulatory (anti-diabetogenic) function. Recent data
also suggest that the DNCD3 cells can develop extra-thymically in
some mouse strains and humans [65].
DNCD3 splenic population from young NOD mice consisted in
a majority of CD3
+(4
28
2) double negative TCRab cells and a
small fraction of CD3
+(4
28
2) double negative TCRcd
+ cells (1–
2%) and NKT cells (0.2–0.4%). Several arguments inferred the
conclusion that the long-lasting anti-diabetogenic effect of NOD
DNCD3 splenic cells was provided by the CD3
+(4
28
2) double
negative TCRab
+ cells rather than CD3
+(4
28
2) double negative
TCRcd
+ cells or NKT cells. Reports showed that the intraepi-
thelial CD3
+(4
+8
2) single positive TCRcd
+ cells exert a suppres-
sogenic effect on the conventional T-cells [66], but the role of
peripheral CD3
+(4
28
2) double negative TCRcd
+ and
CD3
+(4
+8
2) single positive TCRcd
+ cells in autoimmune diabetes
is still controversial [67], since the TCRcd
+ cells associated with
either progression of diabetes [66–73] or protection against
diabetes [39–41,55–57,74]. Our adoptive cell transfer experiments
Table 1. Phenotypic markers expressed by the NOD DNCD3 splenic cells.
Cell markers Mature CD3
+4
+ splenic T-cells (%/average MFI) DNCD3 splenic cells (%/average MFI)
NOD males NOD females NOD males NOD females
CD28
+ 9263.7/180 9861.1/187 7864.3/192 8664.6/199
CD69
+ 10.361.2/114 11.461.4/125 19.262.7/131 16.863.2/127
CD25
low 6.261.9/237 2.560.8/216 19.263.1/248 13.463.1/257
CD25
high 2.260.9/1,020 1.961.1/1,002 0.0860.02/1,021 0.0960.01/1,015
iCTLA-4
+ 2.360.8/ND 2.861.2/ND 0.860.2/ND 0.4560.3/ND
DX5
+ 2.1761.1/ND 1.6560.8/ND 0.460.3/ND 0.260.1/ND
CD1d/a-gal-ceramide TCR
+ 2.960.4/ND 1.760.6/ND 0.1760.1/ND 0.160.08/ND
CD1d/a-unloaded TCR
+ 0.1260.1/ND 0.1160.1/ND 0.1460.1/ND 0.1260.09/ND
TCR Vb 8764.7/ND 8563.8/ND 97.561.1/ND 95.863.2/ND
TCR Vb 1562.2/ND 1362.5/ND 2.161.2/ND 3.961.1/ND
Single-cell suspensions (10
6 cells) isolated from the spleen of 14-day old individual NOD males and females (n=5 per group) were co-stained with CD3-Alexa Fluor700,
CD4-APC, CD8-PerCP Cy5.5 conjugates, and either one of the following Ab-PE conjugates specific for CD28, CD69, CD25, iCTLA-4, DX5, TCR Vb or TCR Vd antigens.
Aliquot cells were co-stained with CD3-Alexa Fluor700, CD4-PE, CD8-PerCP, and a CD1d tetramer unloaded or loaded with a-galactosyl ceramide-APC conjugate. Shown
are the mean values 6 SD for the frequency (%) and single-cell density (MFI) of each phenotypic marker expressed by DNCD3 splenocytes and mature CD4 T-cells
(control) as determined by FACS (*ND, not done).
doi:10.1371/journal.pone.0011427.t001
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splenic cells from young NOD mice showed a lack of anti-
diabetogenic effect of CD3
+(4
28
2) double negative TCRcd
+
splenic cells. The role of NK cells appears to be also unrelated to
autoimmune diabetes [53,54]. Recent data suggest that iNKT cells
may even exacerbate diabetes in mice [75]. Our data showed that
a small number of NK/NKT cells within the DNCD3 splenic
preparations from young NOD mice lacked anti-diabetogenic
effect when tested in a diabetes transfer system like the NOD/Scid
mouse.
An important question that remains to be addressed is why the
DNCD3 regulatory cells allow development of diabetes in adult
NOD mice. One possible explanation is that differentiation of
DNCD3 splenic cells into anti-diabetogenic TR-1-like cells is
greatly impaired by a gradual expansion of Th1 autoreactive cells.
However, only 60–70% of NOD females and 20–40% of NOD
males develop diabetes in adulthood, and this coincides with a
decline of DNCD3 splenic cells in adulthood, which suggests that
at least in part, individual variations in the number and/or
suppressogenic threshold of DNCD3 peripheral cells may also play
a role.
In summary, this study delineates a new cell population of regulatory
cells (DNCD3 splenic cells) in young NOD mice with potential
anti-diabetogenic effect. The phenotype of DNCD3 splenic cells is
CD3
+(CD4
2CD8
2)CD28
+CD69
+CD25
lowFoxp3
2iCTA-4
2TCRab
+
with a predominant Vb13 gene usage. Their suppressive (anti-
diabetogenic) effect relied mainly on the ability to differentiate
into IL-10-secreting TR-1 cells in a Th2-like extra-thymic
environment. Future technologies may allow expansion of
DNCD3 regulatory cells in vitro and provide rational grounds
Figure 6. TCR Vb repertoire of NOD DNCD3 splenic cells. Single-cell suspensions from the spleen and thymus of 14 day-old NOD female (n=4)
and male littermates (n=3) were co-stained with monoclonal antibodies-FITC conjugates specific for several TCR Vb-chains and with CD3-PE, CD4-PE-
Cy7, and CD8-PerCP mAb-conjugates (Bioscience, Palo Alta, CA). Panel A, percentages of TCR Vb families expressed on the cell surface of total
thymocytes (upper panel) and DNCD3
+ gated thymocytes (lower panel) as determined by FACS. Panel B, age-variation in the frequency of TCR Vb13 on
total thymocytes (upper panel) and DNCD3 thymocytes (lower panel) from NOD females (n=3 per each group of age) and males (n=3 per each group
of age) as determined by FACS. Panel C, percentages of TCR Vb families expressed on the cell surface of total splenocytes (upper panel) and DNCD3
splenocytes (lower panel) from the same mice analyzed by FACS as in panel A. Panel D, age-variation in the frequency of TCR Vb13 on total
splenocytes (upper panel) and DNCD3 splenocytes (lower panel) from the same NOD females (n=3 per group of age) and males (n=3 per group of
age) as analyzed by FACS in panel B. Shown is the FACS analysis of a representative NOD female and male from two experiments (significance of
Vb13 family expression on DNCD3 cells between two separate experiments, p#0.005).
doi:10.1371/journal.pone.0011427.g006
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Supporting Information
Figure S1 FACS-sorting of DNCD3 splenic cells from NOD
mice. Single DNCD3 cell suspensions from the spleen of NOD
and NON.NOD mice isolated from a pool of 14 day-old animals
(n=20) were stained with a combination of 2 mg/10
6 cells of
CD4/CD8 Ab-PE and CD3 Ab-APC conjugates. Gated-live cells
(left panel A) were sorted for the CD3+428- population (P2
window) in a FACSAria instrument at 50,000 cell events/min, and
re-sorted under the same conditions (P2 window in panel B)t o
higher than 98% purity. Shown is one of two representative
experiments.
Found at: doi:10.1371/journal.pone.0011427.s001 (1.34 MB TIF)
Figure S2 In Vivo cell cycle division of NOD CD4-8-TCRcd +
splenic cells. A group of NOD/Scid mice (n=6) was infused with
FACS-sorted DNCD3 splenocytes (5610
5 cells/mouse) isolated
from 14 day-old NOD females followed by CFSE injection. Seven
days later, the CFSE+ cells isolated from pooled spleens of CFSE-
labeled NOD/Scid recipients were stained with a combination of
CD4/CD8 Ab-APC and TCRcd Ab-PE conjugates (2 mg Ab/
10
6 cells), and the CFSE dilution factor measured within the CD4-
8-TCRcd-gated population. Shown is the majority of non dividing
CD4-8- double negative TCRcd+ cells (dark histogram) as
compared with non dividing NOD DNCD3 control splenic cells
labeled in vitro with CFSE (dotted histogram).
Found at: doi:10.1371/journal.pone.0011427.s002 (1.39 MB TIF)
Figure S3 In vivo proliferation of DNCD3 splenic cells from
NOD mice at various time-points after birth. Groups of young
NOD littermates of 2, 7, 14, and 28 days of age (n=327 mice per
group) were injected intravenously (i.v.) with 0.1 mg CFSE per
gram of body weight, and seven days later the spleen cells were
harvested, cells from each group were pooled, and stained with
CD4 Ab-PerCP Cy5.5, CD8 Ab-PE, and CD3 Ab-APC
conjugates. The cell cycle divisions of CFSE+, CD3+428- cells
(DNCD3 cells) was determined based on CFSE dilution factor in
FACS using a LSR II instrument (BD Biosciences). The number of
cell cycle divisions was analyzed using the WINlist software 3D
5.0. Shown are the cycles of cell division of CFSE-labeled DNCD3
splenocytes. CFSE serial dilutions of cells labeled in vitro (lower
panel) indicate the number of cell cycle divisions.
Found at: doi:10.1371/journal.pone.0011427.s003 (1.89 MB TIF)
Figure S4 Effect of collagenase method for isolation of
lymphocytes on the CD4/CD8 phenotype. Total thymocytes
from individual mice were treated in vitro with collagenase
preparation as described, then washed in PBS, stained with CD4
and CD8 mAb-dye conjugates, and analyzed by FACS. Shown is a
significant loss of CD4 and CD8 surface expression in one of two
representative experiments.
Found at: doi:10.1371/journal.pone.0011427.s004 (1.61 MB TIF)
Figure S5 Lack of Foxp3 mRNA expression in NOD DNCD3
splenic cells. FACS-sorted DNCD3 splenic cells (10
6 cells), and
negatively-sorted mature splenic CD4+ T-cells (10
6 control cells)
were isolated from 14 day-old female mice (n=10) and stimulated
for 5 days under Th1 or Th2 conditions, or for 1 day under T-reg
conditions (2.5 mg/ml of CD3/CD28 mAb and TGF-b,a s
described. mRNA was amplified in RT-PCR using specific
primers for Foxp3. Lane 1, molecular markers; lane 2, DN cells
stimulated under Th1 conditions; lane 3, DN cells stimulated
under Th2 conditions; lane 4, DN cells stimulated with CD3/
CD28 mAbs and TGF-b, and lane 5, splenic CD4+ mature T-cells
stimulated with CD3/CD28 mAbs alone. Foxp3 transcript was
detected only in splenic CD4+ mature T-cells. Lower panel shows
the GAPDH mRNA amplicons corresponding to each sample
analyzed in the upper panel.
Found at: doi:10.1371/journal.pone.0011427.s005 (1.24 MB TIF)
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